SCHEDULE 13G: Vanguard Group Discloses 5.37% Passive Stake in Akebia Therapeutics

The Vanguard Group has reported a 5.37% beneficial ownership stake in Akebia Therapeutics Inc., holding 12,685,803 common shares as of March 31, 2025.

Summary

• The Vanguard Group, an investment adviser, has filed a Schedule 13G indicating beneficial ownership of 12,685,803 shares of Akebia Therapeutics Inc. common stock.
• This stake represents 5.37% of Akebia Therapeutics Inc.'s outstanding common stock.
• The filing date for the event requiring this statement was March 31, 2025.
• Vanguard holds sole dispositive power over 12,470,283 shares and shared dispositive power over 215,520 shares.
• Vanguard holds shared voting power over 136,460 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a neutral, factual disclosure of a significant passive ownership stake by a reputable institutional investor. While not directly positive or negative about the issuer's performance, a large institutional holding can be perceived as a vote of confidence, hence slightly above neutral.

Positives

• A major institutional investor like The Vanguard Group holding a significant stake (5.37%) can signal confidence in Akebia Therapeutics Inc.
• The passive nature of the investment, as stated in the filing, suggests it is held for investment purposes rather than activist intent, which can provide stability.

Negatives

• The Schedule 13G filing itself does not contain negative financial or operational information about Akebia Therapeutics Inc., as it is solely a disclosure of ownership.

Future Outlook

The Schedule 13G filing does not contain any forward-looking statements or guidance regarding Akebia Therapeutics Inc.'s future performance or The Vanguard Group's investment strategy beyond the certification of passive holding.

Management Comments

• The Vanguard Group certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This Schedule 13G filing is a routine disclosure by a large institutional investor, The Vanguard Group, indicating a passive ownership stake in Akebia Therapeutics Inc. It reflects a standard investment activity within the financial industry, where large asset managers acquire significant, non-controlling positions in publicly traded companies as part of their diversified portfolios. It does not provide specific insights into Akebia Therapeutics Inc.'s competitive position or broader industry trends beyond the fact that it is a publicly traded company attracting institutional investment.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) by a passive institutional investor. It does not contain performance metrics or operational results for Akebia Therapeutics Inc. that would allow for a comparison to industry standards or specific comparable companies/projects. The filing itself adheres to SEC disclosure standards for beneficial ownership.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by The Vanguard Group may provide a degree of stability and confidence, as it indicates a major institutional investor holds a long-term, non-activist position.
• Management: The filing confirms that Vanguard's stake is not for the purpose of influencing control, which suggests less immediate pressure from this particular large shareholder on management decisions.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Akebia Therapeutics Inc. or The Vanguard Group beyond the ongoing passive investment.

Key Dates

Keywords

Akebia Therapeutics Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment